Mr. Pratap Sandhu reports

THE PRECISION PEPTIDE COMPANY INC. ANNOUNCES CLOSING OF LIFE OFFERING OF COMMON SHARES

Further to the news release dated June 11, 2026, The Precision Peptide Company Inc. has closed its previously announced non-brokered private placement of common shares in the capital of the company at a price of 50 cents per share under the listed issuer financing exemption (as defined herein) for gross proceeds of $2-million through the issuance of four million shares.

Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 (Prospectus Exemptions), the LIFE offering was made to purchasers resident in all provinces of Canada, except Quebec, pursuant to the listed issuer financing exemption under Part 5A of NI 45-106. The securities offered under the listed issuer financing exemption are not subject to a hold period in accordance with applicable Canadian securities laws.

In connection with the LIFE offering, the company did not pay any finders' fees.

The company intends to use the net proceeds from the offering for general working capital purposes, to advance its business objectives, to finance marketing initiatives, and to support the procurement of inventory and products.

About The Precision Peptide Company Inc.

Precision Peptide is a publicly traded wellness company focused on advanced peptide formulations and delivery systems. The company is building a next-generation wellness platform that combines scientific formulation, sustainable sourcing and innovative delivery systems, creating products at the intersection of biotechnology and scalable consumer wellness. Products are manufactured in an approved U.S. facility and distributed across North America.

We seek Safe Harbor.